Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Pancreatic islet reserve in type 1 diabetes

Lookup NU author(s): Dr Anneliese Flatt, Professor James ShawORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2021 New York Academy of Sciences.Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by pancreatic islet β cell loss and dysfunction resulting in insulin deficiency and hyperglycemia. During a presymptomatic phase of established β cell autoimmunity, β cell loss may first be evident through assessment of β cell secretory capacity, a measure of functional β cell mass. Reduction in pancreatic islet β cell reserve eventually manifests as impaired first-phase insulin response to glucose and abnormal glucose tolerance, which progresses until the functional capacity for β cell secretion can no longer meet the demand for insulin to control glycemia. A functional β cell mass of ∼25% of normal may be required to avoid symptomatic T1D but is already associated with dysregulated glucagon secretion. With symptomatic T1D, stimulated C-peptide levels >0.60 ng/mL (0.200 pmol/mL) indicate the presence of clinically meaningful residual β cell function for contributing to glycemic control, although even higher residual C-peptide appears necessary for evidencing glucose-dependent islet β and α cell function that may contribute to maintaining (near)normal glycemia. β cell replacement by islet transplantation can restore a physiologic reserve capacity for insulin secretion, confirming thresholds for functional β cell mass required for independence from insulin therapy.

Publication metadata

Author(s): Flatt AJS, Greenbaum CJ, Shaw JAM, Rickels MR

Publication type: Review

Publication status: Published

Journal: Annals of the New York Academy of Sciences

Year: 2021

Volume: 1495

Issue: 1

Pages: 40-54

Print publication date: 01/07/2021

Online publication date: 06/02/2021

Acceptance date: 21/01/2021

ISSN (print): 0077-8923

ISSN (electronic): 1749-6632

Publisher: John Wiley and Sons Inc

URL: https://doi.org/10.1111/nyas.14572

DOI: 10.1111/nyas.14572

PubMed id: 33550589

Share